Baxter withdraws offer for National Medical Care (NMC)
This article was originally published in Clinica
Executive Summary
Baxter has withdrawn its offer to purchase WR Grace's renal care unit, National Medical Care, leaving the way clear for Fresenius to go ahead with its merger plans (see Clinica No 692, p 11). In a letter to Grace chairman Albert Costello on February 22nd, Baxter's chairman and CEO, Vernon Loucks, says: "We have made a fair offer for NMC, which is substantially more favourable to the Grace shareholders than the Fresenius proposals. We will not increase our offer. Since Grace management continues to refuse to discuss our proposal and has determined to go forward with the Fresenius transaction, we hereby withdraw our proposal of January 31st, 1996."
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.